ストックスクリーナーアプリを入手
42.84
2.08%
-0.85
前日終値:
$43.69
開ける：
$43.92
24時間の取引高:
30,220
Relative Volume:
0.08
時価総額：
$2.10B
収益：
$264.38M
当期純損益:
$-109.16M
株価収益率:
-9.9725
EPS:
-4.2958
ネットキャッシュフロー:
$-39.22M
1週間 パフォーマンス:
-7.52%
1か月 パフォーマンス:
+8.72%
6か月 パフォーマンス:
+65.88%
1年 パフォーマンス:
+33.69%
1日の値動き範囲:
$42.58
$44.12
1週間の範囲:
$40.80
$46.80
52週間の値動き範囲:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| MIRM | 42.58 | 2.10B | 264.38M | -109.16M | -39.22M | -4.2958 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.61 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.72 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Phocas Financial Corp. Has $1.48 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Decreased by First Turn Management LLC - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 4.6% After Insider Selling - MarketBeat
MIRM FY2024 EPS Estimate Raised by Cantor Fitzgerald - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Quarterly 10-Q Report - Quartz
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting - Business Wire
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00 - MarketBeat
Mirum Pharmaceuticals stock hits all-time high of $45.28 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high of $45.28 - Investing.com
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth - TipRanks
MIRMMirum Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results - Investing.com
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results By Investing.com - Investing.com Australia
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by GSA Capital Partners LLP - MarketBeat
Mirum Pharmaceuticals earnings beat by $0.15, revenue topped estimates - Investing.com UK
Earnings Outlook For Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Grants 56K Stock Options, 28K RSUs in Key Employee Retention Move | MIRM Stock News - StockTitan
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Tuesday - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):